Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Soleno

Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe

Soleno Therapeutics Inc. (NASDAQ:SLNO) shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe for children with Prader-Willi syndrome (PWS).

Benzinga

Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed.

Investors Business Daily

3 Top Small-Cap Tech Picks for Investors This Month

Wall Street believes these three small companies have significant upside potential.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Meet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505%

Soleno came out from "under the radar" in a big way, CEO Anish Bhatnagar said after SLNO stock more than sextupled in a single day.

Investors Business Daily

Soleno Catapults 505% After Its Pill Controls Hunger In Obesity-Causing Genetic Disease

Soleno said Tuesday its experimental pill helped control hunger signals in a genetic disorder. In response, SLNO stock skyrocketed.

Investors Business Daily

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

Soleno Concludes Type C Meeting With FDA For Diazoxide Choline In Prader-Willi Syndrome

Soleno Therapeutics Inc (NASDAQ: SLNO) said that on January 20, 2022, the Company

Benzinga

Read news from The Economist, FT, and more,
with one subscription

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Rhythm Pharmaceuticals

41 stories

Ionis Pharmaceuticals

Viridian Therapeutics

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.